Larotrectinib and Lovastatin: Interaction Details

Brand names
Larotrectinib
VitrakviIVitrakvi
Lovastatin
AltoprevMevacorAltocor
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Larotrectinib

Brand names
  • VitrakviI
  • Vitrakvi

Lovastatin

Brand names
  • Altoprev
  • Mevacor
  • Altocor

What Happens When You Take Larotrectinib With Lovastatin

What can happen when they are taken together (rated Major)

Increased sensitive exposure and increase in the incidence or severity of adverse reactions

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

Larotrectinib inhibits CYP3A4, so giving it together with a sensitive CYP3A4 substrate is best avoided. When the combination is unavoidable, the patient should be monitored for heightened adverse reactions to the sensitive substrate.

The reason is that larotrectinib may raise of such a substrate, which can raise the frequency or severity of its adverse reactions. In a study of larotrectinib 100 mg twice daily given with midazolam, a sensitive CYP3A4 substrate, midazolam (0 to infinity) and were each 1.7-fold higher than when midazolam was given alone.1

The Larotrectinib and Lovastatin Interaction, Explained

Larotrectinib can raise the amount of lovastatin in your blood. Larotrectinib slows down , a liver enzyme that normally breaks lovastatin down. With more lovastatin around, side effects of the may be more likely or stronger, especially muscle pain, tenderness, or weakness.

This is based on lab data from a similar enzyme test (with a different medicine) rather than on studies of these two drugs together, so it is a predicted risk. Keep taking both as prescribed, and talk with your pharmacist or doctor. Your care team can manage this by watching you more closely or tailoring your treatment. Tell them right away about unexplained muscle pain or dark urine.

Mechanism: Larotrectinib inhibits . Lovastatin is a sensitive CYP3A4 (extensive ), so exposure is expected to increase. Lovastatin is administered as a lactone , but the interaction concerns of the active acid and parent drug, so higher systemic exposure is expected and the direction is increased effect and toxicity.

  • Magnitude: Larotrectinib 100 mg BID increased midazolam (0-inf) and 1.7-fold. No lovastatin-specific data; the effect is extrapolated.
  • Risk: Higher exposure increases the risk of and .
  • Onset: Unspecified. Evidence: theoretical.
  • Management: Avoid . If unavoidable, monitor for adverse reactions (myalgia, weakness, CK and function if symptomatic) and individualize the lovastatin dose.

See the 1 reference behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Larotrectinib and Lovastatin Interact

The likely mechanism

of by larotrectinib

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Larotrectinib and Lovastatin Interaction

The documented advice is to avoid using these two together when possible. If your team decides you need both, they will monitor you for increased side effects of lovastatin.

  • Keep taking both medicines as prescribed unless your prescriber tells you otherwise.
  • Ask your pharmacist or prescriber whether this combination is right for you, or whether another option fits better.
  • Report unexplained muscle pain, tenderness, weakness, or dark urine promptly.
  • Your care team may monitor you more closely, and your lovastatin dose may need to be adjusted and individualized.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Larotrectinib or Lovastatin need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: VITRAKVI oral capsules, oral solution, larotrectinib oral capsules, oral solution

    When larotrectinib 100 mg twice daily was given together with midazolam, a sensitive , the (0 to infinity) and of midazolam were each 1.7-fold higher than with midazolam alone. For 1-hydroxymidazolam, the main of midazolam, the AUC(0 to infinity) and Cmax were both raised 1.4-fold.1

Larotrectinib and Lovastatin: Common Questions

How serious is the Larotrectinib and Lovastatin interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Larotrectinib and Lovastatin interaction managed?

The documented advice is to avoid using these two together when possible. If your team decides you need both, they will monitor you for increased side effects of lovastatin. Keep taking both medicines as prescribed unless your prescriber tells you otherwise. Ask your pharmacist or prescriber whether this combination is right for you, or whether another option fits better. Report unexplained muscle… Management is individual — always follow your own care team's guidance.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Larotrectinib and Lovastatin Interaction

Ask in your own words about taking Larotrectinib and Lovastatin together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (1)

  1. Product Information: VITRAKVI(R) oral capsules, oral solution, larotrectinib oral capsules, oral solution. Bayer HealthCare Pharmaceuticals Inc (per FDA), Whippany, NJ, 2022. DailyMed
Was this write-up helpful?

Other Serious Interactions of Larotrectinib and Lovastatin

Also serious with Larotrectinib

Also serious with Lovastatin

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Larotrectinib

With Lovastatin

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, as soon as they can.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.